Navigation Links
Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
Date:5/5/2010

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. Furthermore, the results associated CD24 expression with the new (seventh) edition of the TNM staging. In summary, the study concluded that high expression of CD24 was a negative independent prognostic factor for progression free and cancer-specific survival in NSCLC.

The metastasis-associated protein CD24 found within a tumor has been identified as a new prognostic factor and stem cell marker; however, the importance of the CD24 in NSCLCs has not been made clear through previously existing research. To clarify the understanding, the present study conducted a retrospective study of prognostic factor analysis by evaluating CD24 expression in 267 consecutive cases of NSCLC. Using a tissue microarray technique the team analyzed the immunohistochemistry that correlated with clinicopathologic parameters.

The specific study findings revealed that CD24-high expression was demonstrated in 33 percent of the NSCLC cases, specifically 87 of 267. Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology (23 percent). Patients with CD24-high tumors also tended to have a higher risk of disease progression and cancer-related death. Furthermore, CD24-high expression aligned with new pathologic stages rather than old p-stages.

Prior to the revision of the TNM staging, the most important conventional prognostic factor for patient survival was tumor stage at the time of diagnosis, including tumor size, pleura invasion, involvement of regional lymph nodes and metastatic spread to distant organs. However, the revised guidelines found age, gender and performance status (PS), in addition to stage, all to be prognostic factors for survival. Within the current study, expression correlated with PS and new p-stage; furthermore, age correlated with progression free survival and cancer-specific survival, regardless of tumor histology.

"Biomarkers that are over-expressed during cancer progression are of special interest because they may not only be used to predict patient outcome but also serve as potential targets in cancer therapy like epidermal growth factor receptor (EGFR) gene," lead investigator Dr. Hyun Ju Lee relays the implications of the research findings.


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The ... MSC Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... performing North American travel partners for the year based on overall business growth in ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired ... its 12th year in 2017. The entrepreneurs will showcase their businesses on February ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate Solutions, ... Series of webinars will start January 31 with a session about understanding healthcare ... health and benefits topics, including employee engagement, pricing transparency, population health and wellness, ...
(Date:1/24/2017)... ... ... His message has been heard by more than 100,000 students and adults ... Joel Feldman, has reached his biggest national audience yet: the three million daily readers ... in circulation in the country, and he hopes it will help spread his message ...
(Date:1/24/2017)... Santa Margarita, CA (PRWEB) , ... January 24, 2017 , ... ... advancement platform for 21st century leadership, has named Hector M. Chavez, Manager, Employee & ... and diabetes treatment center - as its Hispanic Leader of the Month. City of ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- Trifecta Clinical , a leading global provider ... Ward to Vice President of Commercial Operations.  Rick ... the promotion of Ericka Atkinson to Vice ... joins Trifecta from Greenphire where he was Vice President ... positions within the healthcare industry throughout his career.  "Rick ...
(Date:1/24/2017)... Research and Markets has announced the addition of the "Implantable ... to 2025" report to their offering. ... The Global Implantable Medical Devices Market ... the next decade to reach approximately $54.28 billion by 2025 ... include 3D medical printing is expected to develop and find in ...
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. 24, ... ), a leader in the engineering and industrialization of biology ... planet, today announced that it has entered into a definitive ... GNVC ), a clinical-stage company and pioneer in the development ... to integrate and expand upon GenVec,s expertise in adenoviral vectors ...
Breaking Medicine Technology: